Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21
作者：
Einsele, H. [1 ]
Knop, S. [1 ]
Vogel, M. [2 ]
Mueller, J. [3 ]
Kropff, M. [4 ]
Metzner, B. [5 ]
Langer, C. [6 ]
Sayer, H. [7 ]
Jung, W. [8 ]
Duerk, H. A. [9 ]
Salwender, H. [10 ]
Wandt, H. [11 ]
Bassermann, F. [12 ]
Gramatzki, M. [13 ]
Roesler, W. [14 ]
Wolf, H-H [15 ]
Brugger, W. [16 ]
Engelhardt, M. [17 ]
Fischer, T. [18 ]
Liebisch, P. [6 ]
Straka, C. [19 ]
机构：
[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Janssen Cilag GmbH, Neuss, Germany
[3] Acromion GmbH, Frechen, Germany
[4] Univ Klinikum Munster, Munster, Germany
[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany
[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany
[7] Univ Hosp Jena, Jena, Germany
[8] Onkol Univ Med Gottingen, Gottingen, Germany
[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany
[10] Asklepios Klin Altona, Hamburg, Germany
[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany
[12] Tech Univ Munich, Med Klin, Munich, Germany
[13] Univ Klinikum Schleswig Holstein, Kiel, Germany
[14] Univ Klinkum Erlangen, Erlangen, Germany
[15] Univ Hosp Halle, Halle, Saale, Germany
[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany
[17] Univ Freiburg, Freiburg, Germany
[18] Otto von Guericke Univ, Magdeburg, Germany
[19] Schon Klin Starnberger See, Berg, Germany
来源：
LEUKEMIA | 2017年 / 31卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;
D O I：
10.1038/leu.2017.83
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1463 / 1466
页数：5
相关论文
共 50 条
  • [41] Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis
    Mainou, Maria
    Madenidou, Anastasia-Vasiliki
    Liakos, Aris
    Paschos, Paschalis
    Karagiannis, Thomas
    Bekiari, Eleni
    Vlachaki, Efthymia
    Wang, Zhen
    Murad, Mohammad Hassan
    Kumar, Shaji
    Tsapas, Apostolos
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (06) : 563 - 568
  • [42] Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav, V
    Hofmeister, Craig C.
    Almaula, Dhwani K.
    Heffner, Leonard T.
    Gupta, Vikas A.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 1928 - +
  • [43] Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy
    Migkou, Magdalini
    Kastritis, Efstathios
    Roussou, Maria
    Gkotzamanidou, Maria
    Gavriatopoulou, Maria
    Nikitas, Nikitas
    Mparmparoussi, Despina
    Matsouka, Charis
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (04) : 323 - 329
  • [44] High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma
    Wang, Liang
    Wang, Jing-hua
    Liu, Wen-jian
    Wang, Wei-da
    Wang, Hua
    Chen, Xiao-qin
    Geng, Qi-rong
    Lu, Yue
    Xia, Zhong-jun
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 2079 - 2088
  • [45] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Dimopoulos, Meletios
    Wang, Michael
    Maisnar, Vladimir
    Minarik, Jiri
    Bensinger, William
    Mateos, Maria-Victoria
    Obreja, Mihaela
    Blaedel, Julie
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [46] Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma
    Straka, Christian
    Salwender, Hans
    Knop, Stefan
    Vogel, Martin
    Muller, Juergen
    Metzner, Bernd
    Langer, Christian
    Sayer, Herbert
    Jung, Wolfram
    Durk, Heinz A.
    Bassermann, Florian
    Gramatzki, Martin
    Roesler, Wolf
    Wolf, Hans-Heinrich
    Brugger, Wolfram
    Engelhardt, Monika
    Fischer, Thomas
    Liebisch, Peter
    Einsele, Hermann
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (05) : 529 - 542
  • [47] Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction
    Latifoltojar, Arash
    Hall-Craggs, Margaret
    Bainbridge, Alan
    Rabin, Neil
    Popat, Rakesh
    Rismani, Ali
    D'Sa, Shirley
    Dikaios, Nikolaos
    Sokolska, Magdalena
    Antonelli, Michela
    Ourselin, Sebastien
    Yong, Kwee
    Taylor, Stuart A.
    Halligan, Steve
    Punwani, Shonit
    EUROPEAN RADIOLOGY, 2017, 27 (12) : 5325 - 5336
  • [48] Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates
    Terpos, Evangelos
    Kastritis, Efstathios
    Ntanasis-Stathopoulos, Ioannis
    Christoulas, Dimitrios
    Papatheodorou, Athanasios
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Fotiou, Despina
    Ziogas, Dimitrios C.
    Migkou, Magdalini
    Roussou, Maria
    Trougakos, Ioannis P.
    Gavriatopoulou, Maria
    Dinnopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : 400 - 407
  • [49] Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
    Jagannath, Sundar
    Roy, Anuja
    Kish, Jonathan
    Lunacsek, Orsolya
    Globe, Denise
    Eaddy, Michael
    Kuriakose, Emil T.
    Willey, Joanne
    Butler-Bird, Stephanie
    Siegel, David
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (07) : 707 - 717
  • [50] Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
    D'Arena, G.
    Valentini, C. G.
    Pietrantuono, G.
    Guariglia, R.
    Martorelli, M. C.
    Mansueto, G.
    Villani, O.
    Onofrillo, D.
    Falcone, A.
    Specchia, G.
    Semenzato, G.
    Di Renzo, N.
    Mastrullo, L.
    Venditti, A.
    Ferrara, F.
    Palumbo, A.
    Pagano, L.
    Musto, P.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1499 - 1502
12345